NEW YORK (GenomeWeb News) — Gene Logic today said it plans to sell its genomics business to Ocimum Biosolutions for $10 million as it continues to reorganize itself as a drug-repositioning and -development company.
 
Gene Logic said the deal allows it to hold full rights "in perpetuity" to use information from the genomics business to help build its drug-repositioning and -development business.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.